trending Market Intelligence /marketintelligence/en/news-insights/trending/1n3feuiuratmxigaj1lgfa2 content esgSubNav
In This List

Ophthotech adds former Santen CEO to board

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Ophthotech adds former Santen CEO to board

Ophthotech Corp. has elected Adrienne Graves to be a board member, effective Dec. 12.

Graves is the former CEO of Santen Inc., the U.S. arm of Japan-based ophthalmic pharmaceutical company Santen Pharmaceutical Co. Ltd.

In addition, Michael Ross will step down as an independent board member at the end of February 2019.

New York-based Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases.